Kineta, Inc., a Seattle, WA-based clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, secured $1.8m Translation Fund Award supplement from the Wellcome Trust.
The award, based on the positive Phase 1a clinical study results in healthy volunteers, will fund the Phase 1b multiple ascending dose (MAD) clinical trial and position LHF-535 for Phase 2 evaluation in Lassa fever patients where no approved treatment is currently available.
The Wellcome Trust awarded Kineta with a Translation Fund Award of up to $7.2M in 2016 to advance the development of LHF-535 for the treatment of Lassa fever.
Led by CEO Shawn Iadonato, Kineta is a clinical stage biotechnology company committed to developing LHF-535, a first-in-class antiviral treatment with potent activity against Lassa fever, an acute viral illness that is known to be endemic in West Africa, and other arenaviruses. It inhibits virus entry into target host cells and serves to suppress viral replication.